FMC presents results and announces sale of operations in India

FMC Corporation reported revenue of $1,05 billion in the second quarter of 2025, up 1% from the same period in 2024. Net accounting income fell 77% year-over-year ($67,8 million in 2025; $295,2 million in 2024). The company announced its decision to sell its business operations in India.

Revenue growth was driven by a 6% increase in sales volume, particularly in herbicides, diamide-based products, and cyantraniliprole. Average prices fell 3%, influenced by cost-plus contracts with diamide partners and lower manufacturing costs. Exchange rates had a negative impact of 1%. The growth portfolio grew at a high single-digit pace, while the core portfolio remained stable.

In North America, sales fell 5%, impacted by stock-outs in Canada. In Latin America, revenue rose 1% and 5% excluding the currency impact, driven by new active ingredients. Asia saw a 17% drop, affected by lower volumes and prices in India. The EMEA region grew 29%, with strong volumes in herbicides and biologicals.

Operating cash flow fell by $226 million, closing at $66 million. Free cash flow totaled $40 million, a drop of $241 million.

Sale in India

The company announced the sale of its commercial operations in India. The decision stems from challenges in the country. FMC will maintain active ingredient production in India and continue to supply technologies through agreements with the buyer. The sale process is expected to be completed within a year.

With the exit of its Indian operations, FMC adjusted its projections. Revenue for 2025 is expected to range from $4,08 billion to $4,28 billion, a 2% decrease at the midpoint compared to 2024. Adjusted EBITDA projections (US$870 million to US$950 million) and adjusted earnings per share (US$3,26 million to US$3,70 million) were maintained. Free cash flow is projected to remain between $200 million and $400 million.

For the third quarter, the company expects revenue between $1,00 billion and $1,10 billion, a 1% decline at the midpoint. Adjusted earnings per share are expected to grow 28%, reaching $0,98. Adjusted EBITDA is expected to rise 14%, with volume gains and cost reductions offsetting lower prices.

In the fourth quarter, revenue is expected to be between $1,24 billion and $1,34 billion, a 5% increase. Adjusted EBITDA is expected to grow 4%. Adjusted earnings per share may fall 3%, impacted by a comparison base favored by reduced taxation in 2024.